The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer

Lung cancer is the most common cancer and leading cause of cancer death. While targeted therapies have redefined treatment options for non-small cell lung carcinoma (NSCLC) with genetic aberrations such as epidermal growth factor and anaplastic lymphoma kinase, many patients do not harbour these onc...

Descripción completa

Detalles Bibliográficos
Autores principales: Low, Jia Li, Walsh, Robert J., Ang, Yvonne, Chan, Gloria, Soo, Ross A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Immunotherapy for Lung Cancer: Progress, Opportunities and Challenges
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716180/
https://www.ncbi.nlm.nih.gov/pubmed/31497071
http://dx.doi.org/10.1177/1758835919870360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716180/
https://www.ncbi.nlm.nih.gov/pubmed/31497071
http://dx.doi.org/10.1177/1758835919870360

Ejemplares similares